Generation of humanized anti-DNA hydrolyzing catalytic antibodies by complementarity determining region grafting

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 314-318

  Kim, Dong Sik ^a   Lee, Seung Hyun ^a   Kim, Jeong Sun ^b   Lee, Suk Chan ^c   Kwon, Myung Hee ^d   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Chonnam National University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Anti DNA hydrolyzing antibody; Antibody humanization; Catalytic antibody; CDR grafting; Molecular modeling

Indexed keywords

CATALYTIC ANTIBODY; DNA; MONOCLONAL ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

AGAR GEL ELECTROPHORESIS; ANTIBODY PRODUCTION; ANTIBODY STRUCTURE; ARTICLE; CHEMICAL ANALYSIS; CIRCULAR DICHROISM; COMPLEMENTARITY DETERMINING REGION; COMPLEMENTARITY DETERMINING REGION GRAFTING; DNA BINDING; GENE SYNTHESIS; HUMAN; HYDROLYSIS; MOLECULAR CLONING; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, CATALYTIC; ANTIBODIES, MONOCLONAL; COMPLEMENTARITY DETERMINING REGIONS; DNA; HUMANS; HYDROLYSIS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

EID: 58149496086     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.051     Document Type: Article

References (22)

1. Ewert S., Honegger A., and Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 34 (2004) 184-199
2. Rader C., Turner J.M., Heine A., Shabat D., Sinha S.C., Wilson I.A., Lerner R.A., and Barbas C.F. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. J. Mol. Biol. 332 (2003) 889-899
3. Jang Y.J., and Stollar B.D. Anti-DNA antibodies: aspects of structure and pathogenicity. Cell Mol. Life Sci. 60 (2003) 309-320
4. Nevinsky G.A., and Buneva V.N. Human catalytic RNA- and DNA-hydrolyzing antibodies. J. Immunol. Methods 269 (2002) 235-249
5. Gololobov G.V., Rumbley C.A., Rumbley J.N., Schourov D.V., Makarevich O.I., Gabibov A.G., Voss Jr. E.W., and Rodkey L.S. DNA hydrolysis by monoclonal anti-ssDNA autoantibody BV 04-01: origins of catalytic activity. Mol. Immunol. 34 (1997) 1083-1093
6. Baranovskii A.G., Ershova N.A., Buneva V.N., Kanyshkova T.G., Mogelnitskii A.S., Doronin B.M., Boiko A.N., Gusev E.I., Favorova O.O., and Nevinsky G.A. Catalytic heterogeneity of polyclonal DNA-hydrolyzing antibodies from the sera of patients with multiple sclerosis. Immunol. Lett. 76 (2001) 163-167
7. Krasnorutskii M.A., Buneva V.N., and Nevinsky G.A. Antibodies against RNA hydrolyze RNA and DNA. J. Mol. Recognit. 21 (2008) 338-347
8. Kim Y.R., Kim J.S., Lee S.H., Lee W.R., Sohn J.N., Chung Y.C., Shim H.K., Lee S.C., Kwon M.H., and Kim Y.S. Heavy and light chain variable single domains of an anti-DNA binding antibody hydrolyze both double- and single-stranded DNAs without sequence specificity. J. Biol. Chem. 281 (2006) 15287-15295
9. Marion T.N., Krishnan M.R., Desai D.D., Jou N.T., and Tillman D.M. Monoclonal anti-DNA antibodies: structure, specificity, and biology. Methods 11 (1997) 3-11
10. Katz J.B., Limpanasithikul W., and Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J. Exp. Med. 180 (1994) 925-932
11. Park K.J., Lee S.H., Kim T.I., Lee H.W., Lee C.H., Kim E.H., Jang J.Y., Choi K.S., Kwon M.H., and Kim Y.S. A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res. 67 (2007) 7327-7334
12. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
13. Whitelegg N.R., and Rees A.R. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng. 13 (2000) 819-824
14. Park S.Y., Lee W.R., Lee S.C., Kwon M.H., Kim Y.S., and Kim J.S. Crystal structure of single-domain VL of an anti-DNA binding antibody 3D8 scFv and its active site revealed by complex structures of a small molecule and metals. Proteins 71 (2008) 2091-2096
15. Lee H.W., Kim T.I., Chan K.H., Kwon M.H., Kim J.S., Jin M., and Kim Y.S. Inducing rigid local structure around the zinc-binding region by hydrophobic interactions enhances the homotrimerization and apoptotic activity of zinc-free TRAIL. Biochem. Biophys. Res. Commun. 362 (2007) 766-772
16. Kim Y.S., Jones L.S., Dong A., Kendrick B.S., Chang B.S., Manning M.C., Randolph T.W., and Carpenter J.F. Effects of sucrose on conformational equilibria and fluctuations within the native-state ensemble of proteins. Protein Sci. 12 (2003) 1252-1261
17. Ewert S., Huber T., Honegger A., and Pluckthun A. Biophysical properties of human antibody variable domains. J. Mol. Biol. 325 (2003) 531-553
18. Tolun G., and Myers R.S. A real-time DNase assay (ReDA) based on PicoGreen fluorescence. Nucleic Acids Res. 31 (2003) e111
19. Knappik A., Ge L., Honegger A., Pack P., Fischer M., Wellnhofer G., Hoess A., Wolle J., Pluckthun A., and Virnekas B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296 (2000) 57-86
20. Martin A.C., Cheetham J.C., and Rees A.R. Modeling antibody hypervariable loops: a combined algorithm. Proc. Natl. Acad. Sci. USA 86 (1989) 9268-9272
21. Helms L.R., and Wetzel R. Destabilizing loop swaps in the CDRs of an immunoglobulin VL domain. Protein Sci. 4 (1995) 2073-2081
22. Kabat E.A., and Wu T.T. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J. Immunol. 147 (1991) 1709-1719